Keyword: Sun Pharmaceutical
Daiichi and AZ's Enhertu as well as and Astellas and Seattle Genetics' Padcev won FDA nods as China approved rivals to Prevnar and Gardasil.
After years of criticism from the FDA, Sun’s Halol plant still can’t get through an FDA inspection without the agency finding some deficiency.
Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.
A year after facing insider trading claims, Sun Pharma now must fight charges it fired two former employees for refusing to market its meds off-label.
HiFiBiO raises $67 million in series C. Kyowa Kirin wins long-awaited FDA nod for Parkinson's drug Nourianz. SEBI's initial probe clears Sun Pharma.
A SEBI investigation team recommends no further inquiry into the allegations, but the report is still subject to leadership review.
Pfizer's mature drugs plunged in China. AZ and GSK race their oral anemia drugs to Asia. Biotech leaders worry IP crackdown will hurt collaboration.
After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.
Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.
Sun Pharma chief Dilip Shanghvi snared only $3,690 in 2018 pay—including a 1.5-cent salary—as investors questioned its management practices.